GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

papillary RCC and chromophobe RCC. In patients with advanced clear cell renal cell carcinoma (ccRCC), sitravatinib (tyrosine kinase inhibitor) has shown efficacy both alone and in combination with ...

Professor Peter Mulders presented results from the phase 3 ZIRCON study, which evaluated 89 Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma. The increasing detection of renal ...

Clear cell renal cell carcinoma is the most common form of kidney cancer, accounting for 75% of malignant kidney tumors, and is generally associated with poor patient outcomes. With risk factors ...

1Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio. Search for other works by this author on: 2Department of Biostatistics, Health Informatics and Data ...

RCC is further broken down into several subtypes. Some subtypes, such as chromophobe renal cell carcinoma and papillary renal cell carcinoma, are sometimes low-grade tumors. Other RCC subtypes, such ...

(Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first patient ...

1 Cancer Institute, the Second Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou, Zhejiang, China Objective Increasing evidence suggests that cancer-associated inflammation is ...

Squamous cell carcinoma (SCC) of the head and neck originates from the mucosal lining of the upper aerodigestive tract, including the lip, tongue, nasopharynx, oropharynx, larynx and hypopharynx. In ...